Acer Therapeutics Inc. ACER Balance Sheet

Acer therapeutics inc. (ACER)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10
Assets
Current assets:
Cash and cash equivalents
7,007	12,077	16,121	23,488	31,831	41,671	46,185	8,343	12,368	15,644	8,404	1,824	2,822	1,834	5,814	7,847	9,955	12,583	15,592	18,283	9,572	9,906	16,214	19,659	23,644	20,172	5,028	7,834	592	2,237	1,570	4,677	7,109	8,639	9,876	3,812
Prepaid expenses and other current assets
624	807	972	792	778	1,075	-	-	-	881	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	1,144	571	826	-	-	-	-	540	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Subscription receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57	-	-	232	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	836	155	237	-	224	339	932	498	329	403	683	758	1,481	1,565	1,122	1,304	1,694	1,166	1,077	1,188	953	1,005	124	105	119	85
Total current assets
7,631	12,884	17,093	24,280	32,610	42,746	47,329	8,914	13,195	16,526	9,241	1,980	3,060	2,374	6,039	8,245	10,887	13,082	16,154	18,687	10,256	10,665	17,696	21,225	24,767	21,476	6,722	9,000	1,669	3,425	2,523	5,683	7,233	8,745	9,996	3,898
Property and equipment, net
176	193	158	186	210	130	131	67	66	62	5	0	0	6	648	700	765	837	886	918	1,007	1,098	1,234	1,289	1,295	1,226	1,229	1,189	1,265	1,327	1,385	1,390	1,029	953	930	815
Other assets:
Goodwill
7,647	7,647	7,647	7,647	7,647	7,647	7,647	7,647	7,647	7,647	7,647	-	-	272	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development
118	118	118	118	118	118	118	118	118	118	118	-	-	118	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred financing costs
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	500	500	1,000	1,000	-	-	-	-	-	-
Deferred financing costs, net of amortization of $0 and $58,639, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112	158	211	245	27	-	-	-	-	-
Other non-current assets
566	620	523	568	430	20	34	40	16	13	-	-	-	1	489	489	-	496	9	19	29	38	162	166	177	85	96	104	-	-	-	-	-	-	-	-
Total assets
16,140	21,465	25,541	32,801	41,016	50,663	55,260	16,788	21,043	24,368	17,012	1,980	3,060	2,773	7,177	9,435	11,653	14,416	17,051	19,625	11,293	11,802	19,093	22,681	26,239	22,788	8,660	10,952	4,146	5,998	3,936	7,074	8,263	9,698	10,926	4,714
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
344	561	29	1,538	61	1,033	595	861	325	95	539	6	298	383	1,021	577	562	739	1,018	1,148	1,152	702	835	715	696	914	1,156	830	412	534	556	1,681	491	429	495	358
Accounts payable - related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	15	15	-	15	15	15
Accrued expenses
1,171	1,944	2,154	3,171	2,759	4,546	1,559	1,870	2,152	1,937	1,711	335	428	438	1,099	1,455	1,210	1,008	1,041	900	1,272	1,049	1,627	1,228	1,232	1,056	1,209	931	473	358	337	350	576	285	243	335
Other current liabilities
264	263	227	226	164	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	726	1,452	2,178	2,905	2,905	2,905	2,905	1,230	1,230	1,395	1,395	1,395	1,395	1,395	-	-	-	-	-	-	-	-
Notes payable - insurance
-	-	-	-	-	-	-	-	-	-	-	26	91	-	0	37	93	148	-	-	-	149	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,451	-	-	-	-	-	-
Current maturity of loan payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35
Total current liabilities
1,780	2,768	2,412	4,937	2,984	5,580	-	-	-	-	-	368	818	-	2,847	3,523	4,044	4,801	4,964	4,954	5,330	3,132	3,693	3,339	3,324	3,365	3,760	3,157	885	3,352	908	2,047	1,067	730	754	745
Other non-current liabilities
270	326	264	311	245	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	726	1,452	2,178	1,230	1,846	1,989	2,338	2,686	3,035	3,384	-	-	-	-	-	-	-	-
Total liabilities
2,051	3,095	2,676	5,248	3,230	5,580	2,154	2,731	2,478	2,033	2,250	368	818	821	2,847	3,523	4,044	4,801	5,690	6,406	7,509	4,363	5,539	5,328	5,662	6,052	7,318	6,918	1,262	3,659	908	2,047	1,067	-	-	745
Series B Convertible Redeemable Preferred stock, $0.0001 par value; none and 970,238 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016, respectively
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Series A Convertible Redeemable Preferred stock, $0.0001 par value; none and 638,416 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016, respectively
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible Redeemable Preferred stock
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commitments and Contingencies (Note 6)
-	-	-	-	-	-	0	0	0	-	-	-	-	0	-	-	-	-	-	-	0	-	0	0	-	0	0	0	0	0	0	0	0	0	0	0
Series B Convertible Redeemable Preferred stock, $0.0001 par value; none and 970,238 shares authorized, issued and outstanding at December 31, 2017 and 2016, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	12,136	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized 10,000,000 shares; none issued and outstanding
-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock, $0.0001 par value; authorized 150,000,000 shares; 10,101,034 and 10,095,176 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
1	1	1	1	1	1	1	0	74	74	0	76	76	24	71	70	69	69	68	533	282	35	276	276	275	227	79	79	62	230	230	230	57	230	230	184
Additional paid-in capital
95,287	94,619	93,958	93,394	92,586	91,914	91,440	48,426	48,025	47,812	-	-	-	1,147	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid in capital
-	-	-	-	-	-	-	-	-	-	36,098	164,459	164,410	-	163,869	163,446	163,038	162,884	162,253	160,852	148,172	148,724	147,363	146,999	146,569	139,017	118,047	117,743	112,432	109,686	108,017	107,851	107,818	107,541	107,447	98,496
Accumulated deficit
-81,199	-76,250	-71,094	-65,842	-54,801	-46,832	-38,336	-34,370	-29,535	-25,551	-21,337	-162,924	-162,245	-11,357	-159,610	-157,604	-155,499	-153,339	-150,961	-148,167	-	-141,320	-	-	-126,267	-	-	-	-	-	-	-	-	-	-	-
Accumulated deficit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	144,671	-	134,086	129,923	-	122,509	116,785	113,789	109,611	107,577	105,219	103,054	100,680	98,803	97,506	94,712
Total stockholders’ equity
14,088	18,370	22,865	27,552	37,786	45,083	53,105	14,056	18,565	22,335	14,761	1,611	2,241	-10,184	4,330	5,912	7,608	9,615	11,360	13,218	3,783	7,439	13,553	17,352	20,577	16,735	1,341	4,034	2,883	2,339	3,028	5,026	7,195	8,968	10,171	3,968
Total liabilities and stockholders’ equity
16,140	21,465	25,541	32,801	41,016	50,663	55,260	16,788	21,043	24,368	17,012	1,980	3,060	2,773	7,177	9,435	11,653	14,416	17,051	19,625	11,293	11,802	19,093	22,681	26,239	22,788	8,660	10,952	4,146	5,998	3,936	7,074	8,263	9,698	10,926	4,714